Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market is estimated to increase at a Compounded Annual Growth Rate of 22.8% CAGR over the forecast period from 2024 to 2030
The Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Therapeutics (Elafibranor, Ocaliva, Selonsertib, Cenicriviroc), Diagnostics (Imaging Techniques, Diagnostic Tests, Biopsy)).
An Introduction to Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market in 2024
In 2024, the market for non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics continues to expand, driven by the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and NASH worldwide, along with advancements in understanding the disease pathogenesis and the development of targeted treatments. NASH is a progressive form of NAFLD characterized by hepatic inflammation, hepatocyte injury, and fibrosis, which can lead to cirrhosis, liver failure, and hepatocellular carcinoma (HCC). The market for NASH therapeutics includes pharmaceutical agents such as FXR agonists, PPAR agonists, GLP-1 receptor agonists, and ASK1 inhibitors, among others, targeting various pathways involved in hepatic steatosis, inflammation, and fibrosis. Additionally, lifestyle interventions, dietary modifications, weight management programs, and exercise regimens play a crucial role in managing NASH and reducing disease progression. Technological advancements in NASH diagnostics include non-invasive imaging modalities such as transient elastography (TE), magnetic resonance elastography (MRE), and ultrasound-based techniques for assessing hepatic fibrosis and steatosis. Moreover, the identification of circulating biomarkers, genetic markers, and molecular signatures associated with NASH pathology enables early detection, risk stratification, and monitoring of disease progression in at-risk populations. With the increasing recognition of NASH as a major public health concern and the urgent need for effective treatments and diagnostic tools, the market for NASH therapeutics and diagnostics is poised for continued growth and innovation, offering hope for millions of patients affected by this silent epidemic of liver disease.
Market Trend: Increasing Focus on Non-Alcoholic Steatohepatitis (NASH)
A prominent trend in the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is the increasing focus on addressing the rising prevalence and clinical significance of NASH as a major cause of chronic liver disease worldwide. NASH, characterized by liver inflammation and damage due to excess fat accumulation in the liver of individuals who drink little to no alcohol, has emerged as a significant public health concern due to its association with obesity, metabolic syndrome, and type 2 diabetes. This trend is characterized by heightened awareness, research efforts, and clinical trials focused on understanding the pathophysiology of NASH, identifying biomarkers for early diagnosis and risk stratification, and developing effective therapeutic interventions to prevent disease progression and reduce the risk of liver-related complications, including cirrhosis and hepatocellular carcinoma. As healthcare systems and pharmaceutical companies prioritize liver health, metabolic disorders, and preventive medicine, the market for NASH therapeutics and diagnostics is expected to witness significant growth and innovation, driven by the imperative to address the unmet medical needs and economic burden associated with NASH-related liver diseases.
Market Driver: Growing Burden of Obesity and Metabolic Syndrome
The primary driver propelling the NASH therapeutics and diagnostics market is the growing burden of obesity, metabolic syndrome, and related risk factors contributing to the increasing prevalence of NASH worldwide. Obesity, sedentary lifestyles, unhealthy dietary habits, and metabolic dysregulation are major contributors to the development and progression of NASH, making it a significant component of the global epidemic of non-alcoholic fatty liver disease (NAFLD). As the prevalence of obesity and metabolic disorders continues to rise, particularly in developed and developing countries, there is a corresponding increase in the incidence of NASH and its associated complications, including liver fibrosis, cirrhosis, and liver failure. This driver is fueled by demographic trends such as population aging, urbanization, and changes in lifestyle factors, which contribute to the growing burden of metabolic diseases and liver-related disorders. Additionally, advancements in epidemiological research, clinical diagnostics, and imaging modalities enable early detection, risk stratification, and management of individuals at risk of NASH, driving the demand for effective therapeutics and diagnostic tools. As healthcare systems prioritize preventive medicine, lifestyle interventions, and metabolic health initiatives, the market for NASH therapeutics and diagnostics is expected to experience sustained growth and investment, driven by the imperative to improve patient outcomes and reduce the burden of NASH-related liver diseases on individuals, families, and healthcare systems.
Market Opportunity: Development of Targeted Therapies and Precision Diagnostics
An opportunity within the NASH therapeutics and diagnostics market lies in the development of targeted therapies and precision diagnostics that address the diverse pathophysiological mechanisms and patient heterogeneity associated with NASH and NAFLD. Opportunities exist for pharmaceutical companies and diagnostic manufacturers to explore novel therapeutic targets, pathways, and biomarkers involved in the progression of NASH, including hepatic inflammation, oxidative stress, lipid metabolism, and fibrogenesis. Targeted therapies, such as small molecule inhibitors, monoclonal antibodies, and nucleic acid-based therapies, offer potential benefits in reducing liver fat, inflammation, and fibrosis, thereby halting or reversing disease progression in patients with NASH. Additionally, opportunities exist for precision diagnostics, including blood-based biomarker panels, imaging technologies, and non-invasive liver assessments, to enable accurate diagnosis, risk stratification, and monitoring of NASH patients in clinical practice. Collaborations between industry, academia, and regulatory agencies can drive innovation and development of NASH therapeutics and diagnostics that improve patient outcomes, accelerate drug development, and enable personalized medicine approaches in the management of NASH-related liver diseases. As the field of hepatology and metabolic medicine evolves, the market presents opportunities for differentiation, market expansion, and leadership in delivering effective interventions that address the complex needs of patients with NASH and NAFLD.
Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Analysis: Elafibranor
Elafibranor stands out as a frontrunner in the fast-growing segment of Non-alcoholic Steatohepatitis (NASH) therapeutics. This drug has garnered significant attention due to its promising potential in addressing NASH, a condition characterized by fatty liver disease that can progress to more severe liver damage. Elafibranor operates by targeting multiple pathways involved in NASH pathogenesis, including inflammation, lipid metabolism, and fibrosis. Clinical trials have shown encouraging results, demonstrating its efficacy in reducing liver fat content and improving liver function markers. With its unique mechanism of action and demonstrated clinical benefits, Elafibranor is positioned to witness rapid growth in the NASH therapeutics market, offering hope for millions of patients worldwide grappling with this increasingly prevalent liver disorder.
Non alcoholic Steatohepatitis Therapeutics and Diagnostics Competitive Analysis
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAimil Ltd, Bloodoxy Scans And Labs, GE Healthcare, Genfit SA, Gilead Sciences Inc, Intercept Pharmaceuticals Inc, Koninklijke Philips N.V., Novo Nordisk A/S, Siemens Healthineers AG, Takeda Pharmaceutical Company Ltd, Tawazun Health
Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Segmentation
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Companies
Aimil Ltd
Bloodoxy Scans And Labs
GE Healthcare
Genfit SA
Gilead Sciences Inc
Intercept Pharmaceuticals Inc
Koninklijke Philips N.V.
Novo Nordisk A/S
Siemens Healthineers AG
Takeda Pharmaceutical Company Ltd
Tawazun Health
Reasons to Buy the Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Outlook, $ Million, 2021 to 2030
3.2 Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Non alcoholic Steatohepatitis Therapeutics and Diagnostics Industry
4.2 Key Market Trends in Non alcoholic Steatohepatitis Therapeutics and Diagnostics Industry
4.3 Potential Opportunities in Non alcoholic Steatohepatitis Therapeutics and Diagnostics Industry
4.4 Key Challenges in Non alcoholic Steatohepatitis Therapeutics and Diagnostics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Outlook by Segments
7.1 Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Outlook by Segments, $ Million, 2021- 2030
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
8 North America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis and Outlook To 2030
8.1 Introduction to North America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Markets in 2024
8.2 North America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
9 Europe Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Non alcoholic Steatohepatitis Therapeutics and Diagnostics Markets in 2024
9.2 Europe Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Outlook by Segments, 2021-2030
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
10 Asia Pacific Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Non alcoholic Steatohepatitis Therapeutics and Diagnostics Markets in 2024
10.2 Asia Pacific Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
11 South America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis and Outlook To 2030
11.1 Introduction to South America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Markets in 2024
11.2 South America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
12 Middle East and Africa Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Non alcoholic Steatohepatitis Therapeutics and Diagnostics Markets in 2024
12.2 Middle East and Africa Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Non alcoholic Steatohepatitis Therapeutics and Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Aimil Ltd
Bloodoxy Scans And Labs
GE Healthcare
Genfit SA
Gilead Sciences Inc
Intercept Pharmaceuticals Inc
Koninklijke Philips N.V.
Novo Nordisk A/S
Siemens Healthineers AG
Takeda Pharmaceutical Company Ltd
Tawazun Health
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Therapeutics
-Elafibranor
-Ocaliva
-Selonsertib
-Cenicriviroc
Others
Diagnostics
-Imaging Techniques
-Diagnostic Tests
-Biopsy
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
